Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
absolute, abstract, ASC, ASU, blue, Carryforward, CMV, compounded, Conference, construct, construction, cotton, deposit, divert, EU, eventual, expenditure, FDIC, forfeited, Georiga, GHA, heavily, HTGC, identification, immunecompromised, inconsistent, indeterminate, influenza, intrinsic, IPO, IVIG, launching, length, Marietta, milestone, moving, multiplied, nonemerging, nonqualified, oral, OTCQB, overallotment, Palivizumab, pneumoniae, preceding, preliminary, Ramsey, rat, reclassified, refinance, rental, Route, Serum, shortly, simplified, sky, stretch, symbol, Topic, tranche, underwriting, uplisting
Filing tables
Filing exhibits
Related press release
ADMA similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered
Public Accounting Firm
We consent to the incorporation by reference in the registration statement on Form S-8 filed by ADMA Biologics, Inc. of our report dated March 28, 2014, on our audits of the consolidated financial statements of ADMA Biologics, Inc. and Subsidiaries as of December 31, 2013 and 2012 and for the years then ended, included in this Annual Report on Form 10-K of ADMA Biologics, Inc. for the year ended December 31, 2013.
/s/ CohnReznick LLP
Roseland, New Jersey
March 28, 2014